{
    "ticker": "PLUS",
    "name": "Plus Therapeutics, Inc.",
    "description": "Plus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer and other serious diseases. Founded in 2016 and headquartered in Austin, Texas, Plus Therapeutics focuses on advancing its proprietary platform for delivering potent therapeutic agents directly to tumors. The company's lead product candidate, Rhenium-186 NanoLiposome, is designed to provide targeted radiation therapy with the potential to significantly improve patient outcomes in difficult-to-treat cancers. Plus Therapeutics aims to leverage its expertise in nanotechnology and radiation medicine to create treatment options that are both effective and safe, utilizing a patient-centric approach in all stages of development. The company is committed to addressing unmet medical needs and enhancing the quality of life for patients battling cancer through its innovative solutions. In addition to Rhenium-186 NanoLiposome, Plus Therapeutics is exploring additional therapeutic candidates and partnerships to expand its pipeline and bring new hope to patients and their families.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Austin, Texas, USA",
    "founded": "2016",
    "website": "https://www.plustherapeutics.com",
    "ceo": "Marc Hedrick, M.D.",
    "social_media": {
        "twitter": "https://twitter.com/PlusTherapeutics",
        "linkedin": "https://www.linkedin.com/company/plus-therapeutics/"
    },
    "investor_relations": "https://www.plustherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Marc Hedrick, M.D.",
            "position": "CEO"
        },
        {
            "name": "Shawn M. D. D. A. Y. K. G. D. G. G. S. K. Y.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapeutics",
            "products": [
                "Rhenium-186 NanoLiposome"
            ]
        }
    ],
    "seo": {
        "meta_title": "Plus Therapeutics, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Plus Therapeutics, Inc., a biotechnology company focused on developing innovative therapies for cancer treatment. Learn about their lead product, Rhenium-186 NanoLiposome, and commitment to patient-centric solutions.",
        "keywords": [
            "Plus Therapeutics",
            "Cancer Treatment",
            "Biotechnology",
            "Rhenium-186",
            "NanoLiposome",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does Plus Therapeutics specialize in?",
            "answer": "Plus Therapeutics specializes in developing innovative therapies for cancer and serious diseases using advanced drug delivery systems."
        },
        {
            "question": "What is the lead product of Plus Therapeutics?",
            "answer": "The lead product of Plus Therapeutics is Rhenium-186 NanoLiposome, designed for targeted radiation therapy."
        },
        {
            "question": "Where is Plus Therapeutics headquartered?",
            "answer": "Plus Therapeutics is headquartered in Austin, Texas, USA."
        },
        {
            "question": "When was Plus Therapeutics founded?",
            "answer": "Plus Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "CLLS",
        "KPTI",
        "MDGL",
        "CRMD"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}